The design and synthesis of dextran-doxorubicin prodrug-based pH-sensitive drug delivery system for improving chemotherapy efficacy

Xiaoli Zhang,Tian Zhang,Xianbin Ma,Yajun Wang,Yi Lu,Die Jia,Xiaohua Huang,Jiucun Chen,Zhigang Xu,Feiqiu Wen

DOI: https://doi.org/10.1016/j.ajps.2019.10.001

IF: 9.273

2020-09-01

Asian Journal of Pharmaceutical Sciences

Abstract:<p>Tumor cells show acidic conditions compared with normal cells, which further inspires scientist to build nanocarrier responsive to tumor microenvironment (TME) for enhancing tumor therapeutic efficacy. Here, we report a pH-sensitive and biocompatible polyprodrug based on dextran-doxorubicin (DOX) prodrug (DOXDT) for enhanced chemotherapy. High-density DOX component was covalently decorated on the nanocarrier and the drug molecules could be effectively released in the acidic tumor tissue/cells, improving chemotherapy efficacy. Specifically, a dextran-based copolymer was preliminarily prepared by one-step atom transfer radical polymerization (ATRP); then DOX was conjugated on the copolymer component <em>via</em> pH-responsive hydrazone bond. The structure of DOXDT can be well-controlled. The resulting DOXDT was able to further self-assemble into nanoscale micelles with a hydration diameter of about 32.4 nm, which presented excellent micellar stability. Compared to lipid-based drug delivery system, the DOXDT prodrug showed higher drug load capacity up to 23.6%. In addition, excellent stability and smaller size of the nanocarrier contributed to better tissue permeability and tumor suppressive effects <em>in vivo</em>. Hence, this amphipathic DOXDT prodrug is promising in the development of translational DOX formulations, which would be widely applied in cancer therapy.</p><p>Biocompatible polyprodrug based on dextran-doxorubicin (DOXDT) with high drug loading and pH-triggered release for enhanced chemotherapy. </p>

pharmacology & pharmacy